Engineered DNA modifying enzymes: Components of a future strategy to cure HIV/AIDS

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 211-217

  Buchholz, Frank ^a   Hauber, Joachim ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Cure; DNA modifying enzymes; Eradication; HIV; Nucleases; Recombinases

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HISTONE DEACETYLASE; SPACER DNA; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; DISEASE CARRIER; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ENGINEERING; GENE THERAPY; GENOTOXICITY; INFECTION RESISTANCE; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VIRUS LATENCY;

BIOLOGICAL THERAPY; GENETIC ENGINEERING; HIV INFECTIONS; HUMANS;

EID: 84872140973     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.017     Document Type: Review

References (75)

1. Allers K., Hutter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. Evidence for the cure of HIV infection by CCR5 delta32/delta32 stem cell transplantation. Blood 2011, 117:2791-2799.
2. Archin N.M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 2009, 25:207-212.
3. Archin N.M., Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
4. Aubert M., Ryu B.Y., Banks L., Rawlings D.J., Scharenberg A.M., Jerome K.R. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS ONE 2011, 6:e16825.
5. Baltimore D. Gene therapy. Intracellular immunization. Nature 1988, 335:395-396.
6. Blackard J.T., Renjifo B.R., Mwakagile D., Montano M.A., Fawzi W.W., Essex M. Transmission of human immunodeficiency type 1 viruses with intersubtype recombinant long terminal repeat sequences. Virology 1999, 254:220-225.
7. Blazkova J., Chun T.W., Belay B.W., Murray D., Justement J.S., Funk E.K., Nelson A., Hallahan C.W., Moir S., Wender P.A., Fauci A.S. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 2012, 206:765-769.
8. Bogdanove A.J., Voytas D.F. TAL effectors: customizable proteins for DNA targeting. Science 2011, 333:1843-1846.
9. Buchholz F., Hauber J. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods 2011, 53:102-109.
10. Calmy A., Hirschel B., Cooper D.A., Carr A. A new era of antiretroviral drug toxicity. Antivir. Ther. 2009, 14:165-179.
11. Chen R.Y., Accortt N.A., Westfall A.O., Mugavero M.J., Raper J.L., Cloud G.A., Stone B.K., Carter J., Call S., Pisu M., Allison J., Saag M.S. Distribution of health care expenditures for HIV-infected patients. Clin. Infect. Dis. 2006, 42:1003-1010.
12. Chun T.W., Fauci A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012, 26:1261-1268.
13. Coiras M., Lopez-Huertas M.R., Perez-Olmeda M., Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 2009, 7:798-812.
14. Contreras X., Schweneker M., Chen C.S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284:6782-6789.
15. Davey R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., Natarajan V., Lempicki R.A., Adelsberger J.W., Miller K.D., Kovacs J.A., Polis M.A., Walker R.E., Falloon J., Masur H., Gee D., Baseler M., Dimitrov D.S., Fauci A.S., Lane H.C. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:15109-15114.
16. Deeks S.G., Autran B., Berkhout B., Benkirane M., Cairns S., Chomont N., Chun T.W., Churchill M., Mascio M.D., Katlama C., Lafeuillade A., Landay A., Lederman M., Lewin S.R., Maldarelli F., Margolis D., Markowitz M., Martinez-Picado J., Mullins J.I., Mellors J., Moreno S., O'Doherty U., Palmer S., Penicaud M.C., Peterlin M., Poli G., Routy J.P., Rouzioux C., Silvestri G., Stevenson M., Telenti A., Lint C.V., Verdin E., Woolfrey A., Zaia J., Barre-Sinoussi F. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 2012, 12:607-614.
17. Deeks S.G., McCune J.M. Can HIV be cured with stem cell therapy?. Nat. Biotechnol. 2010, 28:807-810.
18. Deeks S.G., Phillips A.N. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009, 338:a3172.
19. Dieffenbach C.W., Fauci A.S. Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 2011, 154:766-771.
20. Durand C.M., Blankson J.N., Siliciano R.F. Developing strategies for HIV-1 eradication. Trends Immunol. 2012, 33:554-562.
21. Dybul M., Fauci A.S., Bartlett J.G., Kaplan J.E., Pau A.K. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 2002, 137:381-433.
22. Edelstein L.C., Micheva-Viteva S., Phelan B.D., Dougherty J.P. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retroviruses 2009, 25:883-887.
23. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
24. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
25. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 2009, 61:953-964.
26. Gabriel R., Lombardo A., Arens A., Miller J.C., Genovese P., Kaeppel C., Nowrouzi A., Bartholomae C.C., Wang J., Friedman G., Holmes M.C., Gregory P.D., Glimm H., Schmidt M., Naldini L., von Kalle C. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 2011, 29:816-823.
27. Geeraert L., Kraus G., Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 2008, 59:487-501.
28. Glaser S., Anastassiadis K., Stewart A.F. Current issues in mouse genome engineering. Nat. Genet. 2005, 37:1187-1193.
29. Gooley T.A., Chien J.W., Pergam S.A., Hingorani S., Sorror M.L., Boeckh M., Martin P.J., Sandmaier B.M., Marr K.A., Appelbaum F.R., Storb R., McDonald G.B. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 2010, 363:2091-2101.
30. Hakre S., Chavez L., Shirakawa K., Verdin E. Epigenetic regulation of HIV latency. Curr. Opin. HIV AIDS 2011, 6:19-24.
31. Hiom K. Coping with DNA double strand breaks. DNA Repair (Amst) 2010, 9:1256-1263.
32. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G.M., Kohn D.B., Gregory P.D., Holmes M.C., Cannon P.M. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 2010, 28:839-847.
33. Hütter G., Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. ScientificWorldJournal. 2011, 11:1068-1076.
34. Hütter G., Nowak D., Mossner M., Ganepola S., Müßig A., Allers K., Schneider T., Hofmann J., Kücherer C., Blau O., Blau I.W., Hofmann W.K., Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
35. Hütter G., Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3years and the search for patient No. 2. AIDS 2011, 25:273-274.
36. Kiem H.P., Jerome K.R., Deeks S.G., McCune J.M. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012, 10:137-147.
37. Lachmann N., Brennig S., Pfaff N., Schermeier H., Dahlmann J., Phaltane R., Gruh I., Modlich U., Schambach A., Baum C., Moritz T. Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system. Gene Ther. 2012, 10.1038/gt.2012.40.
38. Lafeuillade A. Potential strategies for an HIV infection cure. HIV Clin Trials 2011, 12:121-130.
39. Lafeuillade A. Eliminating the HIV reservoir. Curr. HIV/AIDS Rep. 2012, 9:121-131.
40. Lewin S.R., Evans V.A., Elliott J.H., Spire B., Chomont N. Finding a cure for HIV: will it ever be achievable?. J. Int. AIDS Soc. 2011, 14:4.
41. Li T., Huang S., Jiang W.Z., Wright D., Spalding M.H., Weeks D.P., Yang B. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res. 2011, 39:359-372.
42. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 2002, 347:385-394.
43. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
44. Mannheimer S., Friedland G., Matts J., Child C., Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin. Infect. Dis. 2002, 34:1115-1121.
45. Margolis D.M. Eradication therapies for HIV infection: time to begin again. AIDS Res. Hum. Retroviruses 2011, 27:347-353.
46. Margolis D.M. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 2011, 6:25-29.
47. Mariyanna L., Priyadarshini P., Hofmann-Sieber H., Krepstakies M., Walz N., Grundhoff A., Buchholz F., Hildt E., Hauber J. Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS ONE 2012, 7:e31576.
48. McIntyre G.J., Groneman J.L., Yu Y.H., Jaramillo A., Shen S., Applegate T.L. 96 shRNAs designed for maximal coverage of HIV-1 variants. Retrovirology 2009, 6:55.
49. Mussolino C., Morbitzer R., Lutge F., Dannemann N., Lahaye T., Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011, 39:9283-9293.
50. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet. 2011, 12:301-315.
51. Ostrowski S.R. Immune activation in chronic HIV infection. Dan. Med. Bull. 2010, 57:B4122.
52. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 1998, 338:853-860.
53. Palmer S., Josefsson L., Coffin J.M. HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. 2011, 270:550-560.
54. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., Kempf D.J., Mellors J.W., Coffin J.M., King M.S. Low-level viremia persists for at least 7years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3879-3884.
55. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M., Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 2000, 133:21-30.
56. Pattanayak V., Ramirez C.L., Joung J.K., Liu D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 2011, 8:765-770.
57. Perez E.E., Wang J., Miller J.C., Jouvenot Y., Kim K.A., Liu O., Wang N., Lee G., Bartsevich V.V., Lee Y.L., Guschin D.Y., Rupniewski I., Waite A.J., Carpenito C., Carroll R.G., Orange J.S., Urnov F.D., Rebar E.J., Ando D., Gregory P.D., Riley J.L., Holmes M.C., June C.H. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26:808-816.
58. Plana M., Garcia F., Gallart T., Miro J.M., Gatell J.M. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. immunology study group of Spanish EARTH-1 study. Lancet 1998, 352:1194-1195.
59. Porteus M.H., Carroll D. Gene targeting using zinc finger nucleases. Nat. Biotechnol. 2005, 23:967-973.
60. Richman D.D. Antiviral drug resistance. Antiviral Res. 2006, 71:117-121.
61. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
62. Rossi J.J., June C.H., Kohn D.B. Genetic therapies against HIV. Nat. Biotechnol. 2007, 25:1444-1454.
63. Sarkar I., Hauber I., Hauber J., Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007, 316:1912-1915.
64. Schackman B.R., Gebo K.A., Walensky R.P., Losina E., Muccio T., Sax P.E., Weinstein M.C., Seage G.R., Moore R.D., Freedberg K.A. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 2006, 44:990-997.
65. Scherer L.J., Rossi J.J. Ex vivo gene therapy for HIV-1 treatment. Hum. Mol. Genet. 2011, 20:R100-R107.
66. Schiffer J.T., Aubert M., Weber N.D., Mintzer E., Stone D., Jerome K.R. Targeted DNA mutagenesis for the cure of chronic viral infections. J. Virol. 2012, 86:8920-8936.
67. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., Yang H.C., Zhang H., Margolick J.B., Blankson J.N., Siliciano R.F. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
68. Smith M.Z., Wightman F., Lewin S.R. HIV reservoirs and strategies for eradication. Curr. HIV/AIDS Rep. 2012, 9:5-15.
69. Stoddard B.L. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 2011, 19:7-15.
70. Surendranath V., Chusainow J., Hauber J., Buchholz F., Habermann B.H. SeLOX-a locus of recombination site search tool for the detection and directed evolution of site-specific recombination systems. Nucleic Acids Res. 2010, 38:W293-W298.
71. Tebas, P., Levine, B., Binder, G., Hoxie, J., Collman, R., Gregory, P., Holmes, M., Ando, D., June, C., 2011. Disruption of CCR5 in zinc finger nuclease-treated CD4 T cells: phase I trials. In: 18th Conference on Retroviruses and Opportunistic Infections. Paper # 165.
72. Thompson M.A., Aberg J.A., Cahn P., Montaner J.S., Rizzardini G., Telenti A., Gatell J.M., Gunthard H.F., Hammer S.M., Hirsch M.S., Jacobsen D.M., Reiss P., Richman D.D., Volberding P.A., Yeni P., Schooley R.T. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333.
73. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11:636-646.
74. Van Duyne G.D. A structural view of cre-loxp site-specific recombination. Annu. Rev. Biophys. Biomol. Struct. 2001, 30:87-104.
75. van Lunzen J., Fehse B., Hauber J. Gene therapy strategies: can we eradicate HIV?. Curr. HIV/AIDS Rep. 2011, 8:78-84.